Search Results - targeted+protein+degradation

5 Results Sort By:
Inhibitors of MNK Kinase for Targeted Cancer and CNS Therapeutics.
NU 2015-098 (NU 2015-098, NU 2018-036, NU 2025-036) INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* SHORT DESCRIPTION MNK kinase inhibitors that reduce cancer cell viability and proliferation and penetrates the brain for potential treatment of glioblastoma and CNS disorders. BACKGROUND Leukemia and brain...
Published: 5/6/2026   |   Updated: 4/29/2026   |   Inventor(s):  
Keywords(s): AD - Alzheimer’s Disease, AML - Acute myeloid leukemia, ASD - Autism Spectrum Disorder, Bladder cancer, Brain cancer, Breast cancer, Cancer/Oncology, CNS - Central Nervous System, Colon cancer, Lung cancer, Neurodegenerative disease, Pancreatic cancer, Prostate cancer, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets
SHORT DESCRIPTION A targeted-protein degradation platform for intracellular targets, addressing resistant oncogenic and neurodegenerative targets. INVENTORS Shana Kelley* Weinberg College of Arts & Sciences, Department of Chemistry Yi Li * Principal Investigator NU Tech ID: NU 2025-050 IP...
Published: 5/7/2026   |   Updated: 4/27/2026   |   Inventor(s):  
Keywords(s): AD - Alzheimer’s Disease, Biologic, Biomolecular condensates, Cancer/Oncology, Drug delivery, Nanoparticle, Neurodegenerative disease, Neurologic disease, Neurology, PD - Parkinson's Disease, Platform technology, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy. INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* Jindan...
Published: 5/6/2026   |   Updated: 3/5/2026   |   Inventor(s):  
Keywords(s): AUTM26C1, BIAUTM1, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081 INVENTORS Sarki Abdulkadir (PI)* Northwestern University Feinberg School of Medicine, Department of Urology Gary Schiltz (PI)* Weinberg College of Arts and Sciences, Department of Chemistry SHORT DESCRIPTION A small molecule PROTAC technology that degrades DOT1L protein for targeted treatment of leukemia and prostate...
Published: 5/7/2026   |   Updated: 2/3/2026   |   Inventor(s):  
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Leukemia, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
IDO-PROTACs for Improving the Anti-Cancer Immune Response
NU 2020-137 INVENTORS Derek Wainwright* Gary Schiltz SHORT DESCRIPTION IDO-PROTAC that target immunosuppressive IDO activity via degradation ABSTRACT The median survival of primary GBM patients following aggressive surgical intervention, radiotherapy, chemotherapy, and tumor treating fields (TTF) is only ~14-16 months. Indoleamine 2,3-dioxygenase...
Published: 5/6/2026   |   Updated: 5/27/2022   |   Inventor(s):  
Keywords(s): AUTM26C1, BIAUTM1, Brain cancer, Cancer/Oncology, Colon cancer, Endometrial cancer, Immunotherapy, Pancreatic cancer, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics